Filtered By:
Specialty: Cardiology
Drug: Pravastatin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

Pharmacological interventions for asymptomatic carotid stenosis
CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.PMID:37565307 | PMC:PMC10401652 | DOI:10.1002/14651858.CD013573.pub2
Source: Atherosclerosis - August 11, 2023 Category: Cardiology Authors: Caroline Nb Clezar Carolina Dq Flumignan Nicolle Cassola Luis Cu Nakano Virginia Fm Trevisani Ronald Lg Flumignan Source Type: research

Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus
AbstractPurpose of ReviewThe aim of this study is to investigate the protective effects of different statin classes, intensity, and cumulative dose-dependent against primary ischemic stroke in patients with T2DM.Recent FindingsThe Cox hazards model was used to evaluate statin use on primary ischemic stroke. Case group: T2DM patients who received statins; control group: T2DM patients who received no statins during the follow-up. Adjusted hazard ratio (aHR) for primary ischemic stroke was 0.45 (95% CI: 0.44 to 0.46). Cox regression analysis showed significant reductions in primary ischemic stroke incidence in users of differ...
Source: Current Atherosclerosis Reports - July 29, 2023 Category: Cardiology Source Type: research

Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS Study.
CONCLUSIONS: Pravastatin significantly reduced the recurrence rate of all stroke among patients with PCS. Thus, the effect of statin on the recurrence of stroke may differ according to infarction location. PMID: 31554765 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 27, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS.
CONCLUSIONS: Statins showed different influences on the risks of atherothromobotic and lacunar stroke according to postrandomized LDL cholesterol levels. PMID: 31534062 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 20, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons
ConclusionsAmong PWH with statin indication(s), blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin used for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - January 25, 2019 Category: Cardiology Source Type: research

Differences in Statin Utilization and Lipid-Lowering by Race, Ethnicity, and HIV Status in a Real-World Cohort of Persons with Human Immunodeficiency Virus and Uninfected Persons
ConclusionsAmong PWH with statin indication(s), Blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin utilized for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research

Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA.
CONCLUSIONS: The control of both LDL cholesterol and CRP levels appears to be effective for preventing recurrent stroke and TIA in patients with non-cardiogenic ischemic stroke. PMID: 30318492 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - October 16, 2018 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
ConclusionsAmong clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment.Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.ResumenIntroducción y objetivosLa vigente guía de práctica clínica para el tratamiento de la hipercolesterolemia recomienda mantener la terapia intensiva con estatinas de los pacientes tratados con implante de stent farmacoactivo (SFA). Sin embargo, el tratamiento intensivo con estatinas, una vez estabilizado el paciente, con fre...
Source: Revista Espanola de Cardiologia - July 10, 2018 Category: Cardiology Source Type: research

Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event.
CONCLUSIONS: Pravastatin is likely to reduce atherothrombotic stroke in patients enrolled within 6 months after stroke onset. However, the clinical efficacy for prevention of recurrent stroke was not conclusive with earlier statin treatment. PMID: 28924103 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 20, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
Conclusions Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.
Source: Revista Espanola de Cardiologia - July 15, 2017 Category: Cardiology Source Type: research

Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
CONCLUSION: In non-cardiogenic ischemic stroke, pravastatin treatment may reduce vascular inflammation as assessed by Hs-CRP, and higher Hs-CRP levels appeared to increase the risk of recurrent stroke and vascular events. PMID: 28302952 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - March 19, 2017 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients
ConclusionsWith a multivariable prediction model the absolute treatment effect of a statin on MACE for individual elderly patients with and without vascular disease can be quantified. Because of high ARRs, treating all patients is more beneficial than prediction-based treatment for secondary prevention of MACE. For primary prevention of MACE, the prediction model can be used to identify those patients who benefit meaningfully from statin therapy.
Source: Clinical Research in Cardiology - August 22, 2016 Category: Cardiology Source Type: research

Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation.
Conclusions:In patients with mild-to-moderate CKD, only strong statins were associated with lower risk compared with no statin, but regular statins were not. It is possible that taking a strong statin from the early stage of CKD is useful for suppression of cardiovascular events. PMID: 25739954 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 24, 2015 Category: Cardiology Authors: Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kaikita K, Oshima S, Nakao K, Shimomura H, Tsunoda R, Hirose T, Kajiwara I, Matsumura T, Nakamura N, Yamamoto N, Koide S, Oka H, Morikami Y, Sakaino N, Matsui K, Ogawa H, on behalf of the Kumamoto Inter Tags: Circ J Source Type: research